Inform Genomics, Tesaro deal

Tesaro will use Inform Genomics' bioinformatics and genomic platforms to evaluate the risk of chemotherapy-induced nausea and vomiting (CINV) in patients who receive "certain" moderately emetogenic chemotherapy regimens and standard antiemetic therapy without a neurokinin 1 (NK1) substance P receptor (TACR1) antagonist. Inform Genomics and Tesaro declined to disclose details. ...